Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome

Daniela Weiskopf(La Jolla Institute for Immunology), Katharina S. Schmitz(Erasmus MC), Matthijs P. Raadsen(Erasmus MC), Alba Grifoni(La Jolla Institute for Immunology), Nisreen M.A. Okba(Erasmus MC), Henrik Endeman(Erasmus MC), Johannes P. C. van den Akker(Erasmus MC), Richard Molenkamp(Erasmus MC), Marion Koopmans(Erasmus MC), Eric C. M. Van Gorp(Erasmus MC), Bart L. Haagmans(Erasmus MC), Rik L. de Swart(Erasmus MC), Alessandro Sette(La Jolla Institute for Immunology), Rory D. de Vries(Erasmus MC)
Science Immunology
June 26, 2020
Cited by 993Open Access
Full Text

Abstract

T cells in 10 out of 10 and 8 out of 10 patients, respectively. We also detected low levels of SARS-CoV-2-reactive T cells in 2 out of 10 healthy controls not previously exposed to SARS-CoV-2, which is indicative of cross-reactivity due to past infection with 'common cold' coronaviruses. The strongest T-cell responses were directed to the spike (S) surface glycoprotein, and SARS-CoV-2-specific T cells predominantly produced effector and Th1 cytokines, although Th2 and Th17 cytokines were also detected. Furthermore, we studied T-cell kinetics and showed that SARS-CoV-2-specific T cells are present relatively early and increase over time. Collectively, these data shed light on the potential variations in T-cell responses as a function of disease severity, an issue that is key to understanding the potential role of immunopathology in the disease, and also inform vaccine design and evaluation.


Related Papers

No related papers found

Powered by citation graph analysis